NYSE:KOD - Kodiak Sciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.00 +0.57 (+8.86 %) (As of 03/26/2019 04:00 PM ET)Previous Close$6.43Today's Range$6.43 - $7.046052-Week Range$5.65 - $11.10Volume56,129 shsAverage Volume64,149 shsMarket Capitalization$257.81 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California. Receive KOD News and Ratings via Email Sign-up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSE:KOD Previous Symbol CUSIPN/A CIKN/A Webwww.kodiak.com Phone650-281-0850Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares36,830,000Market Cap$257.81 million Next Earnings Date3/29/2019 (Estimated) OptionableNot Optionable Kodiak Sciences (NYSE:KOD) Frequently Asked Questions What is Kodiak Sciences' stock symbol? Kodiak Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "KOD." How were Kodiak Sciences' earnings last quarter? Kodiak Sciences Inc. (NYSE:KOD) released its quarterly earnings results on Friday, November, 16th. The company reported ($1.33) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $1.07. View Kodiak Sciences' Earnings History. When is Kodiak Sciences' next earnings date? Kodiak Sciences is scheduled to release their next quarterly earnings announcement on Friday, March 29th 2019. View Earnings Estimates for Kodiak Sciences. What price target have analysts set for KOD? 4 brokers have issued 12-month target prices for Kodiak Sciences' stock. Their forecasts range from $14.00 to $22.50. On average, they expect Kodiak Sciences' share price to reach $19.1250 in the next year. This suggests a possible upside of 173.2% from the stock's current price. View Analyst Price Targets for Kodiak Sciences. What is the consensus analysts' recommendation for Kodiak Sciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kodiak Sciences. Has Kodiak Sciences been receiving favorable news coverage? Press coverage about KOD stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kodiak Sciences earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. Who are some of Kodiak Sciences' key competitors? Some companies that are related to Kodiak Sciences include Mesoblast (MSB), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Theratechnologies (TH), Biotest (BIO), Polynovo (PNV), Oxford BioMedica (OXB), Senesco Technologies (ELOX), Starpharma (SPL), Neptune Wellness Solutions (NEPT), Enochian Biosciences (ENOB), Monash IVF Group (MVF), Emblem (EMC), IMV (IMV) and BELLUS Health (BLU). What other stocks do shareholders of Kodiak Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Intel (INTC), Teladoc Health (TDOC), General Electric (GE), Advanced Micro Devices (AMD), Global Blood Therapeutics (GBT), Canopy Growth (CGC) and Mcdonald's (MCD). Who are Kodiak Sciences' key executives? Kodiak Sciences' management team includes the folowing people: Dr. Victor Perlroth, Co-Founder, Chairman, CEO & Pres (Age 45)Mr. John A. Borgeson MBA, CPA, Sr. VP & CFO (Age 57)Dr. Hong Liang, Sr. VP of Discovery Medicine (Age 46)Dr. Jason S. Ehrlich M.D., Ph.D., Chief Medical Officer & Chief Devel. Officer (Age 42)Dr. Joel Naor M.D., MSc, MBA, VP of Clinical R&D Operations When did Kodiak Sciences IPO? (KOD) raised $126 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays and Chardan were co-managers. When does the company's lock-up period expire? Kodiak Sciences' lock-up period expires on Tuesday, April 2nd. Kodiak Sciences had issued 9,000,000 shares in its initial public offering on October 4th. The total size of the offering was $90,000,000 based on an initial share price of $10.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company. Who are Kodiak Sciences' major shareholders? Kodiak Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.51%), venBio Select Advisor LLC (2.45%), Jennison Associates LLC (2.17%), BlackRock Inc. (1.20%), Northern Trust Corp (0.19%) and Geode Capital Management LLC (0.18%). View Institutional Ownership Trends for Kodiak Sciences. Which institutional investors are buying Kodiak Sciences stock? KOD stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, venBio Select Advisor LLC, Jennison Associates LLC, BlackRock Inc., Northern Trust Corp, Geode Capital Management LLC, Geode Capital Management LLC and Pura Vida Investments LLC. View Insider Buying and Selling for Kodiak Sciences. How do I buy shares of Kodiak Sciences? Shares of KOD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Kodiak Sciences' stock price today? One share of KOD stock can currently be purchased for approximately $7.00. How big of a company is Kodiak Sciences? Kodiak Sciences has a market capitalization of $257.81 million. What is Kodiak Sciences' official website? The official website for Kodiak Sciences is http://www.kodiak.com. How can I contact Kodiak Sciences? The company can be reached via phone at 650-281-0850. MarketBeat Community Rating for Kodiak Sciences (NYSE KOD)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 33 (Vote Outperform)Underperform Votes: 42 (Vote Underperform)Total Votes: 75MarketBeat's community ratings are surveys of what our community members think about Kodiak Sciences and other stocks. Vote "Outperform" if you believe KOD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KOD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: What is a back-end load?